Vu Lan T, Baxter-Lowe Lee Ann, Garcia John, McEnhill Marilyn, Summers Philip, Hirose Ryutaro, Lee Marsha, Stock Peter G
Department of Surgery, University of California at San Francisco, San Francisco, CA 94143-0780, USA.
Arch Surg. 2011 Jul;146(7):824-9. doi: 10.1001/archsurg.2011.147.
To determine the impact of HLA-DR mismatching on rejection, graft survival, and sensitization in a local allocation system that emphasizes donor quality rather than HLA antigen matching for pediatric patients and to determine the likelihood of finding an appropriate donor based on HLA-DR mismatch.
Retrospective cohort study.
A single institution.
A total of 178 patients younger than 21 years who underwent kidney transplantation with daclizumab induction between 1997 and 2006.
The association between HLA-DR mismatching and rejection or graft survival was determined using survival analysis. Sensitization was defined as a posttransplantation panel reactive antibody level greater than 0% in patients with a pretransplantation level of 0%.
Median follow-up was 4.1 years (interquartile range, 2.1-6.1 years). One- and 5-year graft survival rates were 97% and 82%, respectively. HLA-DRB1 mismatches were a significant risk factor for rejection; patients with 1- or 2-HLA-DRB1 mismatches had 1.7 times greater odds of rejection than those with 0-HLA-DR mismatches (P = .006). HLA-DRB1 mismatching was not a significant risk factor for either graft failure or sensitization, but history of rejection was an independent predictor of graft failure (hazard ratio, 7.7; P = .01) and sensitization (odds ratio, 9.7; P = .001). Although avoiding HLA-DRB1 mismatching reduces rejection, the probability of finding ABO-matched local donors younger than 35 years without DR mismatches was extremely low.
Although avoiding HLA-DRB1 mismatching is beneficial, the likelihood of finding an HLA-DRB1-matched donor should also be considered in donor selection.
在一个强调供体质量而非 HLA 抗原匹配的儿童患者本地分配系统中,确定 HLA - DR 错配在排斥反应、移植物存活及致敏方面的影响,并基于 HLA - DR 错配确定找到合适供体的可能性。
回顾性队列研究。
单一机构。
1997 年至 2006 年间共 178 例 21 岁以下接受达利珠单抗诱导的肾移植患者。
采用生存分析确定 HLA - DR 错配与排斥反应或移植物存活之间的关联。致敏定义为移植前水平为 0%的患者移植后群体反应性抗体水平大于 0%。
中位随访时间为 4.1 年(四分位间距,2.1 - 6.1 年)。1 年和 5 年移植物存活率分别为 97%和 82%。HLA - DRB1 错配是排斥反应的显著危险因素;有 1 个或 2 个 HLA - DRB1 错配的患者发生排斥反应的几率比无 HLA - DR 错配的患者高 1.7 倍(P = 0.006)。HLA - DRB1 错配对于移植物失败或致敏均不是显著危险因素,但排斥反应史是移植物失败(风险比,7.7;P = 0.01)和致敏(优势比,9.7;P = 0.001)的独立预测因素。虽然避免 HLA - DRB1 错配可降低排斥反应,但找到 ABO 血型匹配且年龄小于 35 岁且无 DR 错配的本地供体的概率极低。
虽然避免 HLA - DRB1 错配有益,但在供体选择时也应考虑找到 HLA - DRB1 匹配供体的可能性。